(NASDAQ: PHVS) Pharvaris Nv's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.88%.
Pharvaris Nv's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast PHVS's revenue for 2026 to be $1,019,473,908, with the lowest PHVS revenue forecast at $626,229,663, and the highest PHVS revenue forecast at $1,412,772,385. On average, 2 Wall Street analysts forecast PHVS's revenue for 2027 to be $3,065,797,426, with the lowest PHVS revenue forecast at $990,296,497, and the highest PHVS revenue forecast at $5,141,298,354.
In 2028, PHVS is forecast to generate $12,717,391,957 in revenue, with the lowest revenue forecast at $9,238,609,437 and the highest revenue forecast at $16,196,174,477.